India’s top-ranked drug firm, Sun Pharmaceutical Industries Ltd., plunged into a loss for the first quarter of fiscal year 2021, dented by the US price fixing settlement of a subsidiary and the yo-yoing lock-down situation in some parts of that market, which led to temporary closures of clinics.
Sun’s Taro Pharmaceuticals USA, Inc. arm reported settlements and loss contingencies of $478.9m, reflecting the one-time settlement charge of $418.9m...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?